Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0001209191-23-007048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-03 | 2023-02-01 | RXRX | Larson Tina Marriott | Pres, COO | A - Grant | $0.00 | +226.8K | 422.8K | +116% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $8.55 | -3,093 | 429.4K | -0.7% | -$26.4K |
| D | 2023-02-03 | 2023-02-01 | RXRX | Larson Tina Marriott | Pres, COO | A - Grant | $0.00 | +434.1K | 434.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-01 | A | A | 9,732 | $0.00 | 432,540 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-02-01 | A | A | 217,061 | $0.00 | 422,808 | D | — | — | (F2) Includes 2093 shares acquired under the Recursion stock purchase plan on May 20, 2022. |
| 3 | Common | Class A Common Stock | 2023-02-01 | F | D | 3,093 | $8.55 | 429,447 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-02-01 | A | A | 434,122 | $0.00 | 434,122 | D | $8.55 · — to 2033-02-01 | 434,122 Class A Common Stock | (F5) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |